A meta-analysis suggests that high doses of psilocybin may alleviate depressive symptoms similarly to the SSRI drug escitalopram. While the effect size was small, psilocybin outperformed placebo in clinical trials, though study design flaws could have led to overestimated results. The findings indicate that psilocybin, particularly in high doses, may offer a new avenue for treating depression, comparable to existing antidepressants.
